Table 13.
Liquid biopsy in reproductive system cancers
| Cancer | Liquid biomarker | Origin | Tendency | Downstream target | Function | Reference |
|---|---|---|---|---|---|---|
| Cervical cancer | CTCs | Peripheral blood | up | Prognostic biomarker | 490 | |
| ccfHPV-DNA | Plasma | Efficacy monitoring biomarker | 478 | |||
| HOTAIR, PVT1, XLOC_000303, AL592284.1 | Plasma | up | Early diagnostic biomarker | 482 | ||
| miR-21, -25, -29a, -200a, -486-5p | Serum | up | Early diagnostic biomarker, Disease progression biomarker | 483 | ||
| miR-196a | Serum | up | Disease progression biomarker, Prognostic biomarker | 484 | ||
| miR-425-5p | Serum | up | Prognostic biomarker | 485 | ||
| ESR1, ERBB2 mutation | Plasma | up | Efficacy monitoring biomarker | 486 | ||
| Endometrial cancer | CTCs | Peripheral blood | up | Early diagnostic biomarker | 498 | |
| CK-20 | Peripheral blood | up | Tumor aggressiveness biomarker, Tumor recurrence biomarker | 550 | ||
| CTNNB1, KRAS, PTEN, PIK3CA | Plasma | up | Tumor recurrence biomarker, Efficacy monitoring biomarker | 500 | ||
| DNA methylation | Urine | up | Early diagnostic biomarker | 509 | ||
| Ovarian Cancer | claudin | Serum exosome | up | Early diagnostic biomarker | 523 | |
| miR-1307, miR-375 | Serum exosome | up | Early diagnostic biomarker | 524 | ||
| Prostatic carcinoma | CTCs | Peripheral blood | up | Prognostic biomarker | 530 | |
| cfDNA mutation | Serum | up | Early diagnostic biomarker | 531 | ||
| cfDNA | Plasma | up | Efficacy monitoring biomarker, Prognostic biomarker | 532 | ||
| miR-21 | Serum | up | Efficacy monitoring biomarker | 538 | ||
| miR-141, miR-146b-3p, miR-194 | Serum | up | Prognostic biomarker | 539 |